CIK 0001061983
- Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 943291317
- Phone
- +1 650-624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,320,469
- in 18 filings, $12.5M under 10b5-1 plans
Net −$13,320,469. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Blum Robert I −$9.7M President & CEO sold 34% of stake
- Malik Fady Ibraham −$1.3M EVP Research & Development sold 12% of stake
- Hessekiel Jeffrey −$795K Chief Legal & Admin Officer sold 14% of stake
- Callos Andrew −$702K EVP, Chief Commercial Officer sold 15% of stake
- PARSHALL B LYNNE −$631K Director sold 63% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-06 | Malik Fady Ibraham EVP Research & Development | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −28,605 | 57,209 | ||
| 2024-01-31 | Blum Robert I President & CEO | Exercise or conversion 10b5-1 | +12,500 | $6.67 | $83K | 454,297 |
| 2024-01-31 | Blum Robert I President & CEO | Sale 10b5-1 | −12,500 | $79.57 | $995K | 441,797 |
| 2024-01-31 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −12,500 | 130,994 | ||
| 2024-01-19 | Blum Robert I President & CEO | Exercise or conversion 10b5-1 | +12,500 | $6.67 | $83K | 454,297 |
| 2024-01-19 | Blum Robert I President & CEO | Sale 10b5-1 | −12,500 | $81.42 | $1.0M | 441,797 |
| 2024-01-19 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −12,500 | 143,494 | ||
| 2024-01-12 | HENDERSON JOHN T Director | Exercise or conversion 10b5-1 | +5,000 | $4.44 | $22K | 47,632 |
| 2024-01-12 | HENDERSON JOHN T Director | Sale 10b5-1 | −5,000 | $85.14 | $426K | 42,632 |
| 2024-01-12 | HENDERSON JOHN T Director | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 5,000 | ||
| 2024-01-04 | Malik Fady Ibraham EVP Research & Development | Exercise or conversion 10b5-1 | +11,678 | $7.96 | $93K | 162,651 |
| 2024-01-04 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −11,678 | $86.98 | $1.0M | 150,973 |
| 2024-01-04 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −4,000 | $86.99 | $348K | 146,973 |
| 2024-01-04 | Malik Fady Ibraham EVP Research & Development | Exercise or conversion · Incentive Stock Option (Right to Buy) 10b5-1 | −11,678 | 0 | ||
| 2024-01-02 | Wysenski Nancy Director | Grant or award | +74 | $84.12 | $6K | 17,156 |
| 2024-01-02 | WIERENGA WENDALL Director | Grant or award | +74 | $84.12 | $6K | 18,727 |
| 2024-01-02 | SMITH SANDFORD D Director | Grant or award | +148 | $84.12 | $12K | 18,801 |
| 2024-01-02 | Kaye Edward M. MD Director | Grant or award | +148 | $84.12 | $12K | 19,317 |
| 2024-01-02 | HENDERSON JOHN T Director | Grant or award | +252 | $84.12 | $21K | 42,632 |
| 2024-01-02 | Harrington Robert Arthur Director | Grant or award | +148 | $84.12 | $12K | 11,521 |
Page 36 of 45 · 885 trades